SECURITIES AND EXCHANGE COMMISSION
                           Washington, D. C.  20549

                                   FORM 10-Q


                  QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934


                      For the Quarter Ended December 31, 1995

                          Commission File Number 0-12948


                               CHEMFAB CORPORATION
               (Exact name of registrant as specified in its charter)


                  Delaware                                  03-0221503
                  (State or other jurisdiction of        (I.R.S. Employer
                  incorporation or organization)         Identification No.)

                  701 Daniel Webster Highway 
                  Merrimack, New Hampshire                    03054
                  (Address of principal executive office)   (Zip Code)


                  Registrant's telephone number including
                  area code:                              (603) 424-9000



    Indicate by check mark whether the registrant (1) has filed all  reports
    required to be filed by  Section 13 or 15 (d) of the Securities Exchange
    Act of 1934 during the  preceding 12 months (or for such  shorter period
    that the registrant was required to file such reports), and (2) has been
    subject to such filing requirements for the past 90 days.

                               YES   X    NO_____.
                                   -----

    Indicate  the number  of  shares outstanding  of  each of  the  issuer's
    classes of common stock, as of the latest practicable date.


        Class                             Outstanding at February 2, 1996
        Common Stock, $ .10 par value           5,301,446 shares


                             CHEMFAB CORPORATION
                                    INDEX


    Part I - Financial Information:                              Page No.
                                                                 --------

    Item 1 -Financial Statements

         Consolidated Balance Sheets at December                 3 - 4  
         31, 1995 and June 30, 1995

         Consolidated Statements of Income for                       5  
         the Three Months and Six Months Ended 
         December 31, 1995 and January 1, 1995            

         Consolidated Statements of Cash Flows                       6
         for the Six Months Ended December 31, 1995
         and January 1, 1995

         Notes to Consolidated Financial Statements              7 - 8  

    Item 2 -Management's Discussion and Analysis of              8 - 11
            Financial Condition and Results of Operations        

    Part II - Other Information:                

      Item 4    - Submission of Matters to a Vote of
                     Security Holders                                12

      Item 6(a) - Exhibits                                           12

      Item 6(b) - Reports on Form 8-K                                12

      Signatures                                                     13


<TABLE>
<S><C>

                            PART I - FINANCIAL INFORMATION
                            ------------------------------

                                 CHEMFAB CORPORATION
                             CONSOLIDATED BALANCE SHEETS


                                                           Dec. 31,          June 30,
                                                             1995              1995
                                                         ------------      ------------
                                                         (Unaudited)
Current assets:
    Cash and cash equivalents                          $   3,800,000     $   3,780,000
    Receivables:
         Trade                                            15,400,000        16,009,000

         Retainages                                          149,000           148,000
         Other                                               182,000           324,000
    Costs and estimated earnings in excess of 
        billings on uncompleted contracts                  1,259,000           692,000
    Inventories                                           13,773,000        13,110,000
    Prepaid expenses, and other                              718,000           901,000
    Deferred tax assets                                    1,197,000         1,152,000
                                                         -----------       -----------
    Total current assets                                  36,478,000        36,116,000

    
    Property, plant and equipment at cost                 38,121,000        36,869,000
         Less accumulated depreciation
            and amortization                              18,356,000        17,036,000
                                                         -----------       -----------
                                                          19,765,000        19,833,000

    Goodwill, net                                         11,520,000        12,260,000
    Investments in joint ventures and 
        other assets                                       2,360,000         2,410,000
                                                         -----------       -----------
    Total assets                                       $  70,123,000     $  70,619,000
                                                         ===========       ===========

</TABLE>



See accompanying Notes to Consolidated Financial Statements

<TABLE>
<S><C>

                                 CHEMFAB CORPORATION
                             CONSOLIDATED BALANCE SHEETS

                            

                                                           Dec. 31,          June 30,
                                                             1995              1995
                                                          ----------        ----------
                                                         (Unaudited)
Current liabilities:
    Accounts payable and accrued
         expenses                                      $   8,224,000     $   8,757,000
    Accrued income taxes                                     549,000         1,736,000
    Billings in excess of costs and 
         estimated earnings on
         uncompleted contracts                               249,000           122,000
                                                         -----------       -----------
    Total current liabilities                              9,022,000        10,615,000


Long-term debt                                             5,668,000         8,132,000
Deferred income taxes                                      1,491,000         1,551,000

Shareholders' equity:
    Preferred stock, par value $.50:
         authorized - 1,000,000 shares,
         none issued                                          -                 -
    Common stock, par value $.10:
         authorized - 15,000,000 shares;
         issued and outstanding - 5,299,821
         at December 31, 1995 and 5,235,646
         at June 30, 1995                                    530,000           524,000
    Additional paid-in capital                            17,414,000        16,609,000
    Retained earnings                                     36,731,000        33,551,000
    Foreign currency translation
         adjustment                                         (733,000)         (363,000)
                                                         -----------       -----------

Total shareholders' equity                                53,942,000        50,321,000
                                                         -----------       -----------
Total liabilities and shareholders' equity             $  70,123,000     $  70,619,000
                                                         ===========       ===========


</TABLE>


See accompanying Notes to Consolidated Financial Statements





<TABLE>
<S><C>

                                 CHEMFAB CORPORATION
                          CONSOLIDATED STATEMENTS OF INCOME
                                    (Unaudited)


                                                   Three Months Ended                    Six Months Ended
                                             ------------------------------       --------------------------------
                                             Dec. 31, 1995     Jan. 1, 1995       Dec. 31, 1995       Jan. 1, 1995
                                             -------------     ------------       -------------       ------------

  Net sales                                  $   20,885,000    $   15,501,000     $   39,351,000    $   29,223,000
  Cost of sales                                  13,943,000        10,746,000         26,510,000        20,105,000
                                                -----------       -----------        -----------       -----------

  Gross profit                                    6,942,000         4,755,000         12,841,000         9,118,000
  Selling, general and
     administrative expenses                      3,621,000         2,753,000          6,882,000         5,529,000
  Research and development expenses                 571,000           489,000          1,116,000           971,000
  Other expense (income), net                        31,000           (57,000)            30,000           (63,000)
  Interest expense                                  157,000             7,000            339,000            13,000
  Interest income                                   (59,000)          (96,000)          (103,000)         (182,000)
  Results of equity operations                            0           114,000                  0           137,000
                                                -----------       -----------        -----------       -----------

  Income before income taxes                      2,621,000         1,545,000          4,577,000         2,713,000

  Provision for income taxes                        800,000           401,000          1,397,000           746,000
                                                -----------       -----------        -----------       -----------

  Net income                                 $    1,821,000    $    1,144,000     $    3,180,000    $    1,967,000
                                                ===========       ===========        ===========       ===========

  Weighted average common and
   common equivalent shares                       5,474,000         5,311,000          5,446,000         5,300,000
                                                ===========       ===========        ===========       ===========

  Earnings per common share                          $ 0.33            $ 0.22             $ 0.58            $ 0.37
                                                     ======            ======             ======            ======



</TABLE>


  See accompanying Notes to Consolidated Financial Statements.



<TABLE>
<S><C>

                             CHEMFAB CORPORATION
                    CONSOLIDATED STATEMENTS OF CASH FLOWS
                    -------------------------------------
                                (Unaudited)

                                                                        Six Months Ended
                                                                   ------------------------------
                                                                    12/31/95             1/1/95
                                                                   ----------           ---------
Cash flows from operating activities:

   Net income                                                    $  3,180,000       $   1,967,000

   Adjustments to reconcile net income to net
     cash provided by operating activities:
        Depreciation and amortization                               1,992,000           1,449,000
        Results of equity operations                                        0             137,000
        Change in assets and liabilities:
           Receivables                                                594,000             532,000
           Costs and estimated earnings in excess
             of billing on uncompleted contracts, net                (567,000)           (152,000)
           Inventories                                               (748,000)         (1,204,000)
           Prepaid expenses and other                                 178,000            (744,000)
           Other assets long-term                                    (139,000)           (296,000)
           Accounts payable and accrued expenses                     (270,000)           (340,000)
           Accrued income taxes                                    (1,169,000)           (728,000)
           Deferred tax liabilities                                   (60,000)                  0
           Deferred  tax assets                                       (45,000)                  0
                                                                  -----------         -----------
           Total adjustments                                         (234,000)         (1,346,000)
                                                                  -----------         -----------

           Net cash provided by operating activities                2,946,000             621,000

   Cash flows from investing activities:
        Capital expenditures (net)                                 (1,399,000)           (898,000)
                                                                  -----------         -----------
           Net cash used in investing activities                   (1,399,000)           (898,000)

   Cash flows from financing activities:
        Repayment of long-term debt                                (2,309,000)                  0
        Proceeds from excercise of stock options                      812,000             180,000
                                                                  -----------         -----------
           Net cash (used in) provided by financing activities     (1,497,000)            180,000

   Effect of exchange rate changes on cash                            (30,000)             74,000
                                                                  -----------         -----------
   Net increase (decrease)  in cash & marketable securities            20,000             (23,000)

   Cash and marketable securities at beginning of year              3,780,000           7,923,000

   Cash and marketable securities at end of period               $  3,800,000       $   7,900,000
                                                                  ===========         ===========


   Interest paid                                                 $    169,000       $       6,000
   Taxes paid                                                    $  2,317,000       $   1,455,000

   
</TABLE>


    See accompanying Notes to Consolidated Financial Statements




    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

    Note 1 The consolidated financial statements of Chemfab Corporation (the
    Company) included in this report reflect all  adjustments (consisting of
    only normally  recurring accruals) which, in the  opinion of management,
    are necessary  for a  fair presentation  of  the consolidated  financial
    position at December  31, 1995 and  June 30, 1995  and the  consolidated
    statements of income and cash flows for the three months  and six months
    ended December 31,  1995 and January 1, 1995.   The unaudited results of
    operations  for  the  interim   periods  reported  are  not  necessarily
    indicative of results to be expected for the year.


    Certain  notes and other information have been condensed or omitted from
    these interim  financial statements.  The  statements, therefore, should
    be read  in conjunction with  the consolidated financial  statements and
    related  notes included in the Chemfab Corporation Annual Report on Form
    10-K for the year ended June 30, 1995 (file no. 0-12948).

    Note 2 Inventories consist of the following:

    <TABLE>
    <S><C>

                                       Dec. 31, 1995   June 30,1995
                                       -------------   ------------

               Finished Goods            $ 4,294,000    $ 3,953,000
               Work in Process             4,769,000      5,089,000
               Raw Materials               4,710,000      4,068,000
                                          __________     __________
                                         $13,773,000    $13,110,000

    </TABLE>


    Note 3 In connection with obtaining incentive grants from the Industrial
    Development Authority of Ireland, to subsidize investments in plant  and
    equipment in Ireland the Company's Irish subsidiary, Chemfab Europe, has
    agreed to restrict repatriation  of 410,000 Irish pounds (U.S. $656,000) 
    of its retained earnings to fund repayment of the grants in the event of
    default under the agreement.   Chemfab Corporation  has also provided  a
    parent company guarantee in the event  that  the subsidiary's  equity so
    restricted is not sufficient to repay any amount due.


    Various  lawsuits and claims are  pending or have  been asserted against
    the Company,  including the matter  previously disclosed by  the Company
    involving the Bennington Landfill Superfund site, in Bennington Vermont.
    Although  the outcome of such matters cannot be predicted with certainty
    and some  lawsuits or  claims  may be  disposed  of unfavorably  to  the
    Company,  management  believes  their  disposition, to  the  extent  not
    covered by  insurance, will not  have a  material adverse effect  on the
    Company's financial condition and results of operations.

    Note 4 Subsequent Event

    On February 1, 1996, Chemfab Corporation's Board of Directors declared a
    3 for 2 stock split of the Company's common stock.

    The stock  split will be  effected in the  form of a  50% stock dividend
    and,  upon   completion  of   the  transaction,  the   Company's  shares
    outstanding will increase to approximately 7,950,000 shares.   The stock
    split  will be applicable to all shareholders  of record at the close of
    business on February 12, 1996, and the payable date will be February 22,
    1996.

    ITEM 2       Management's Discussion and Analysis of Financial Condition
                 and Results of Operations

    Three Months Ended December 31, 1995

    Net Sales

    The Company's consolidated net sales for the three months ended December
    31,   1995,  the  second  quarter  of  fiscal  1996,  increased  35%  to
    $20,885,000  from $15,501,000  for the  same period  in the  prior year.
    Revenue  growth  was achieved  in both  the  U.S. and  European business
    operations  and reflected the positive  impact of the Company's February
    1995 acquisition  of the Tygaflor fluoropolymer  products business based
    in England.  The impact of changes in foreign currency exchange rates on
    reported  revenue growth was immaterial.  

    Engineered  Products  -  U.S.  Sourced sales  (which  include  all  non-
    architectural  product  sales  from  the  Company's  U.S.  manufacturing
    plants;  principal geographic markets are the Americas and the Far East)
    increased 10% to $10,420,000 from $9,466,000 for the same period  in the
    prior  year.   This sales  increase was  the result  of strength  in the
    Company's  communications,   food  processing  and   protective  systems
    markets,  which was partially offset  by softness in  both the aerospace
    and energy and environment markets. 

    Engineered Products - Europe Sourced  sales (which include product sales
    from the Company's European  manufacturing plants; principal  geographic
    markets are Western Europe, Africa and the Middle East) increased 81% to
    $7,240,000 from  $4,009,000 for the same period in the prior year.  This
    increase  was  due primarily  to the  February  1995 acquisition  of the
    Tyg aflor  business which has since been combined with the Company's pre-
    existing United Kingdom subsidiary.  Had this acquisition not occurred, 
    it is estimated that European Sourced revenues would have increased by 
    approximately 10% for the quarter. 

    Architectural Product sales increased  59% to $3,225,000 from $2,026,000
    for the second quarter of the prior fiscal year.  Architectural products
    were  sold principally to the  Company's Japanese joint venture company,
    Nitto  Chemfab  Co., Ltd.,  during the  second  quarter of  fiscal 1996.
    Architectural  product  sales  are  expected to  continue  to  be strong
    through the end  of the current  fiscal year due primarily  to continued
    strong demand in the Japanese market.

    Gross Profit Margins

    Gross profit margins as a percentage of consolidated net sales were 33%,
    up from 31% in   the second quarter of the prior year.   The increase in
    gross margins  is principally attributable  to the leveraging  effect of
    increased revenues on a relatively stable overhead cost structure. 

    Selling, Administrative, Research and Development Expenses

    Selling, general and administrative expenses increased 30% to $3,621,000
    from  $2,753,000 for  the  second quarter  of  fiscal 1996.    Increased
    expenditures  were principally the result of the combined effects of the
    acquisition  of  the  Tygaflor  business  and  a  somewhat  higher  cost
    structure to support the growth of the underlying business.   Absent the
    impact of the Tygaflor  business, it is estimated that  selling, general
    and administrative expenses would  have increased approximately 13% over
    the  level of  the  second quarter  of  last year.    The percentage  of
    selling, general and administrative expenses to total revenues decreased
    to 17% as compared to 18% for the second quarter of fiscal 1995.

    Research and development expenses were $571,000, an increase of 17% from
    last year's level of $489,000.  This level of spending, at approximately
    3% of  total revenues,  is  consistent with recent, as  well as planned,
    levels of research and development spending.

    Interest Expense (Income)

    The  Company had  net interest  expense of  $98,000 for  the three-month
    period  ended  December 31,  1995, compared  to  net interest  income of
    $89,000  for  the same  period  in  the prior  year.    This change  was
    principally due to the use of previously invested cash and  the issuance
    of  long-term debt  to finance the acquisition of  the Tygaflor business
    in February 1995.

    Six Months Ended December 31, 1995

    Net Sales

    The Company's consolidated net  sales for the six months  ended December
    31, 1995,  the first half of  fiscal 1996, increased 35%  to $39,351,000
    from $29,223,000 for the same period in the prior year.   Revenue growth
    was  achieved  in both  the U.S.  and  European business  operations and
    reflected the positive impact of the Company's February 1995 acquisition
    of the Tygaflor fluoropolymer  products business based in England.   The
    impact of changes in foreign currency exchange rates on reported revenue
    growth was immaterial.  

    Engineered  Products  -  U.S.  Sourced  sales  (which  include all  non-
    architectural  product  sales  from  the  Company's  U.S.  manufacturing
    plants;  principal geographic markets are the Americas and the Far East)
    increased 4% to $19,323,000 from $18,653,000  for the same period in the
    prior  year.   This sales  increase was  the result  of strength  in the
    Company's  communications,  food   processing  and  protective   systems
    markets, which was  partially offset  by softness in  the aerospace  and
    energy and environment markets.  It is expected that revenues from sales
    of U.S. Sourced - Engineered Products for the second half of fiscal 1996
    will show continued growth compared to the same period a year ago. 

    Engineered Products -  Europe Sourced sales (which include product sales
    from  the Company's European  manufacturing plants; principal geographic
    markets are Western Europe, Africa and the Middle East) increased 82% to
    $13,516,000 from $7,427,000 for the same period in the prior year.  This
    increase  was  due primarily  to the  February  1995 acquisition  of the
    Tygaflor  business  which has  been  combined  with the  Company's  pre-
    existing United Kingdom subsidiary.  Had  this acquisition not occurred,
    it is estimated that  European Sourced revenues would have  increased by
    approximately 10% compared with the first half of last year.

    Architectural Product sales increased 107% to $6,512,000 from $3,143,000
    for the  first  six months  of  the prior  fiscal  year.   Architectural
    products were  principally sold to the Company's  Japanese joint venture
    company, Nitto Chemfab Co.,  Ltd., during the first half of fiscal 1996.
    Architectural  product  sales are  expected  to  continue to  be  strong
    through  the end of  the current fiscal year  due primarily to continued
    strong demand in the Japanese market.


    Gross Profit Margins

    Gross profit margins as a percentage of consolidated net sales were 33%,
    up from 31% in  the first half of the prior year.  The increase in gross
    margins  is  principally  attributable   to  the  leveraging  effect  of
    increased revenues on a relatively stable overhead cost structure. 


    Selling, Administrative, Research and Development Expenses

    Selling, general and administrative expenses increased 24% to $6,882,000
    from  $5,529,000  for  the  second  half  of  fiscal  1996.    Increased
    expenditures  were principally the result of the combined effects of the
    acquisition  of  the  Tygaflor  business  and  a  somewhat  higher  cost
    structure to  support the growth of the underlying business.  Absent the
    impact of the Tygaflor  business, it is estimated that  selling, general
    and administrative  expenses would have increased  approximately 6% over
    the  level of the first  half of last year.   The percentage of selling,
    general and administrative expenses to  total revenues, decreased to 17%
    as compared to 19% for the first six months of fiscal 1995.

    Research and  development expenses were  $1,116,000, an increase  of 15%
    from  last  year's  level of  $971,000.    This  level  of spending,  at
    approximately 3% of total revenues,  is consistent with  recent, as well
    as planned, levels of research and development spending.

    Interest Expense (Income)

    The Company  had  net interest  expense of  $236,000 for  the six  month
    period  ended  December 31,  1995, compared  to  net interest  income of
    $169,000  for the  same  period in  the  prior year.    This change  was
    principally due to  the use of previously invested cash and the issuance
    of  long-term  debt to finance the acquisition of  the Tygaflor business
    in February, 1995.

    Liquidity and Capital Resources

    During  the  six  month period  ended  December  31,  1995, the  Company
    generated $2,946,000  of cash  from  operations.   The Company  invested
    $1,399,000  in  property,  plant  and  equipment  additions  and  repaid
    $2,309,000 of its long-term debt.  The Company also received $812,000 in
    cash  proceeds and  related  tax benefits  from  the exercise  of  stock
    options during this period.

    Working  capital increased to $27,456,000  as compared to $25,501,000 at
    the end  of fiscal  1995.   As  of December  31, 1995,  the Company  had
    approximately  $6.6 million  of  additional credit  available under  its
    domestic  and international  borrowing facilities.   Management believes
    that the combination of cash on hand, cash expected to be generated from
    operations, and available credit facilities, will be adequate to finance
    operations  during calendar  1996 and  to deal  with any  liabilities or
    contingencies  described  in  Note   3  to  the  Consolidated  Financial
    Statements.


                           PART II - OTHER INFORMATION
                           ---------------------------

    ITEM 4 - Submission of Matters to a Vote of Security Holders

    On   October  26,  1995,  the   Company  held  its   Annual  Meeting  of
    Shareholders.   At the meeting, Shareholders voted to elect directors of
    the  Corporation; to  increase  the number  of  shares of  common  stock
    authorized  for issuance  under the  Corporation's Amended  and Restated
    1991 Stock  Option Plan  from 700,000 to  1,000,000; and  to ratify  the
    selection   of  Ernst  &  Young  LLP  as  independent  auditors  of  the
    Corporation for the year ended June 30, 1996.

    The vote tally for these actions is a follows:

    Directors                               For       Against     Abstain
    --------------------                 ---------    -------     -------

    Paul M. Cook                         4,206,728    309,350         0

    Warren C. Cook                       4,206,718    309,360         0

    Robert E. McGill III                 4,206,728    309,350         0

    James E. McGrath                     4,206,728    309,350         0

    Duane C. Montopoli                   4,206,718    309,360         0

    Nicholas Pappas                      4,206,728    309,350         0


    Stock Option Amendment               2,624,184    591,632   224,957

    Ernst & Young                        4,467,121      1,104    47,853


    ITEM 6 - Exhibits and Reports on Form 8-K

         6(a) Exhibits

              10 (a)(12) First Amendment to Amended and Restated 
                         1991 Stock Option Plan.

         6(b) Reports on Form 8-K
              None.  


                             CHEMFAB CORPORATION


                                 SIGNATURES
                                 ----------

    PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE
    REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE
    UNDERSIGNED THEREUNTO DULY AUTHORIZED.


    CHEMFAB CORPORATION
    (Registrant)



    by:/S/ Duane C. Montopoli                     
    Duane C. Montopoli      
    President and Chief Executive Officer



    by:/S/ William H. Everett                     
    William H. Everett
    Vice President-Finance and Administration
    (Principal Financial Officer)



    by:/S/ Laurence E. Richard                   
    Laurence E. Richard
    Controller
    (Principal Accounting Officer)



    Date:  February 13, 1996